What is it about?
This paper presents a predictive survival model to estimate risk scores for metastatic castration resistant prostate cancer (mCRPC) patients at 12, 18, 24 and 30-months after trial enrollment based on clinical features of each patient.
Featured Image
Why is it important?
Metastatic castration resistant prostate cancer (mCRPC) is one of the most common cancers with a poor prognosis. We have achieved a high predictive rate (iAUC = 0.779) using boosting strategy and building a model using only five features.
Perspectives
The present study focused on clinical features only. Additional possibilities to improve the performance of the models would be to add molecular level information, such as gene expression data, to training and test sets.
Mr Mehrad Mahmoudian
University of Turku
Read the Original
This page is a summary of: A predictive model of overall survival in patients with metastatic castration-resistant prostate cancer, F1000Research, November 2016, Faculty of 1000, Ltd.,
DOI: 10.12688/f1000research.8192.1.
You can read the full text:
Contributors
The following have contributed to this page
